Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT06870981 · ClinicalTrials.gov registry record

Optimizing Nutrition and Milk (Opti-NuM) Project

A clinical trial of Growth & Development and Very Low Birth Weight Baby, sponsored by The Hospital for Sick Children.

Recruiting
Registry status
1,100
Enrollment target
6
Study locations

NCT06870981 is a study of Growth & Development and Very Low Birth Weight Baby that is actively recruiting participants, run by The Hospital for Sick Children. The registered enrollment target is 1,100 participants. The trial reports 6 study locations across 3 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT06870981, a study of Growth & Development and Very Low Birth Weight Baby, is actively recruiting participants, sponsored by The Hospital for Sick Children.

RECRUITING
Registry status
1,100 participants
Enrollment target
6
Study locations

Study Summary

Early nutrition critically influences growth, neurodevelopment and morbidity among infants born of very low birth weight (VLBW), but current one-size-fits-all feeding regimes do not optimally support these vulnerable infants. There is increasing interest in "precision nutrition" approaches, but it is unclear which Human Milk (HM) components require personalized adjustment of doses. Previous efforts have focused on macronutrients, but HM also contains essential micronutrients as well as non-nutrient bioactive components that shape the gut microbiome. Further, it is unclear if or how parental factors (e.g. body mass index, diet) and infant factors (e.g. genetics, gut microbiota, sex, acuity) influence relationships between early nutrition and growth, neurodevelopment and morbidity. Understanding these complex relationships is paramount to developing effective personalized HM feeding strategies for VLBW infants. This is the overarching goal of the proposed Optimizing Nutrition and Milk (Opti-NuM) Project. The Opti-NuM Project brings together two established research platforms with complementary expertise and resources: 1) the MaxiMoM Program\* with its clinically embedded translational neonatal feeding trial network in Toronto (Dr. Deborah O'Connor, Dr. Sharon Unger) and 2) the International Milk Composition (IMiC) Consortium, a world-renowned multidisciplinary network of HM researchers and data scientists collaborating to understand how the myriad of HM components contribute "as a whole" to infant growth and development, using systems biology and machine learning approaches. Members of the IMiC Corsortium that will work with on this study are located at the University of Manitoba (Dr. Meghan Azad), University of California (Dr. Lars Bode) and Stanford (Dr. Nima Aghaeepour).

Interventions

  • OTHER Opti-NuM is an observational secondary use of data/samples study, the investigators will analyze information and specimens from the MaxiMoM platform RCTs. No interventions form part of this study.

Study Locations (6)

Ontario

  • Sunnybrook Health Sciences Centre - Toronto
  • The Hospital for Sick Children - Toronto
  • Mount Sinai Hospital - Toronto

California

  • Stanford University - Palo Alto
  • University of California - San Diego - San Diego

Manitoba

  • University of Manitoba - Winnipeg

Trial Details

FieldValue
Enrollment Target 1,100 participants
Start Date 2010-10-01
Est. Completion 2027-12

Sponsor

The Hospital for Sick Children

23 total trials

What the Registry Record Tells You About NCT06870981

The ClinicalTrials.gov registry entry for NCT06870981 describes a study currently listed as recruiting, categorized as an unspecified phase. The registered enrollment target is 1,100 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is The Hospital for Sick Children, which has 23 total studies on file at ClinicalTrials.gov.

The record links to 8 conditions, with Growth & Development appearing as the primary indexed condition, and to 1 intervention - of which Opti-NuM is an observational secondary use of data/samples study, the investigators will analyze information and specimens from the MaxiMoM platform RCTs. No interventions form part of this study. is the first listed.

NCT06870981 reports 6 study locations spanning 3 distinct geographic areas - top geographies include Ontario, California, Manitoba.

Frequently Asked Questions

What is clinical trial NCT06870981 about?

NCT06870981 is a clinical study titled "Optimizing Nutrition and Milk (Opti-NuM) Project". Early nutrition critically influences growth, neurodevelopment and morbidity among infants born of very low birth weight (VLBW), but current one-size-fits-all feeding regimes do not optimally support these vulnerable infants. There is increasing interest in "precision nutrition" approaches, but it i...

What is the current status of trial NCT06870981?

This trial is currently recruiting. The enrollment target is 1,100 participants. The study started on 2010-10-01. Estimated completion is 2027-12.

What conditions does trial NCT06870981 study?

This clinical trial studies the following conditions: Growth & Development, Very Low Birth Weight Baby, Early Nutrition and the Preterm Infant, Nutritional Requirements, Human Milk Fortification.

What interventions are being tested in trial NCT06870981?

The interventions under investigation include: Opti-NuM is an observational secondary use of data/samples study, the investigators will analyze information and specimens from the MaxiMoM platform RCTs. No interventions form part of this study. (OTHER).

Who is sponsoring clinical trial NCT06870981?

This trial is sponsored by The Hospital for Sick Children, which has 23 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT06870981 being conducted?

This trial has 6 study locations across California, Manitoba, Ontario. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Growth & Development

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.